A new clinical study has been conducted by Lipotec to assess the anti-wrinkle efficacy of Argireline peptide at a concentration of 2%. The new test shows remarkable improvement of skin appearance after just one week of treatment.
The test was performed on a panel of 24 female volunteers aged 35 to 45 years old, who applied a cream containing the peptide on half of the face, especially on the crow’s feet area, and a placebo cream on the other half, twice daily.
Skin topography was quantitatively evaluated after measurements by FOITS (Fast Optical In vivo Topometry of human Skin) technique at the beginning and at the end of the treatment. At the end of the seven days of treatment, values showed a statistically significant decrease in the average volume and length of the wrinkles by 20.6% and 15.9% respectively, with a cream containing 2% Argireline peptide solution C. The launch of Argireline peptide by Lipotec opened the door to a new generation of anti-ageing active ingredients. Its mechanism of action was a technological innovation: the modulation of muscle contraction to attenuate and reduce wrinkles induced by over-stimulation of facial muscles, through topical formulations, thus offering a topical alternative to more invasive existing methods.
The new in vivo test with Argireline peptide offers new cosmetic strategies that enable claims based on faster benefits for end-users, showing visible skin rejuvenation in just one week.
